Espace MicroCaps is glad to invite you to its Summer 5to7 Cocktail at the Bier Markt Montreal on Wednesday, June 8 at 5:00pm. Our quarterly events are the perfect occasion to network with likeminded investors while discovering new non-resources investment opportunities in the Canadian microcap space.

Where: Bier Markt Montreal, 1221 René-Lévesque W, Montreal

When: Wednesday June 8, at 5:00pm (please arrive before 5:25pm for the first presentation)

Cost: FREE

The first 75 participants to register and to show up at the event before 5:25pm will receive a 10$ coupon for a free drink of their choice. Appetizers will be served during the cocktail as well.

To reserve your spot: Espace MicroCaps Summer 5to7 Cocktail Event

The presenting companies have been hand-picked based on the attractiveness of their business model, market opportunity and fundamentals.

Imaflex (TSX Venture: IFX)

Description: Imaflex is primarily a provider of polyethylene films to converters, who process film into a finished product. The converting process involves printing the required information on the film that Imaflex supplies them based on their end-customer’s needs. Imaflex also manufactures bags that are sold for a variety of uses, including garbage bags. Additionally, the Company produces specialized metallized film for specific agricultural usage to increase efficiency. Imaflex operates four manufacturing facilities, two of which are located in the Province of Québec, in Montréal and in Victoriaville, and two others located in Thomasville, North Carolina, in the United States. The company is profitable and has been growing revenue nicely the last couple of years (+14% in 2015)

The opportunity: We typically like investment opportunities where we can get a free option on the pipeline of products or technologies that a company is developing. Imaflex owns many patents on very promising technologies that are close to being commercialized. We think that the potential of these products is currently not priced into the stock and that is why we feel Imaflex might be a compelling opportunity. The company also released impressive financial results for the first quarter of 2016. Make sure to be there on time to learn more about Imalfex’s business and pipeline of new products.

ProMIS Neurosciences (TSX: PMN)

Description: ProMIS is a development stage biotech company that discovers and develops precision therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s Disease (AD) and Amyotrophic Lateral Sclerosis (ALS – also called Lou Gherig’s Disease), based on the research work of Dr. Neil Cashman, Professor at the University of British Columbia (UBC) and Chief Science Officer at ProMIS. The company already owns a rich intellectual property, notably their ProMIS and Collective Coordinates algorithms, and is currently conducting in-vitro validation studies to identify preclinical assets for the treatment of Alzheimer.

The opportunity: A recent scientific consensus seems to support Dr. Cashman’s science. Alzheimer costs billions of dollars in healthcare every year, not to mention consequences for the affected individuals and their families, and still today no efficient treatment exists.  The addressable market is huge and the successful development of quality preclinical assets should catch the attention of large pharmaceutical companies. If their in-vitro studies show that ProMIS is on the right path, we anticipate a significant rise in share price. Eventually, we think that the company will be acquired for the value of its current and future intellectual property. Also note that ProMIS is seeking a partner to pursue its Amyotrophic Lateral Sclerosis (ALS) development program.

Hamilton Thorne (TSX Venture: HTL)

Description: Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems that reduce cost, increase productivity, improve results and enable breakthroughs in assisted reproductive technologies (ART) and developmental biology research markets. Hamilton Thorne’s laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures.

Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Novartis, Pfizer, and Dow Chemical.

The opportunity: Hamilton Thorne is profitable and trades at a valuation of ~9 times earnings and 1.1 times revenue based on 2015 numbers while its competitors trade at much higher valuations. The company has a solid balance sheet with more than $4.4M US dollars in cash and low interest debt from an institution with which it has a long time relationship. Moreover, CEO David Wolf plans to do one or more acquisitions in the coming months to accelerate his growth strategy. With many potential targets in the pipeline and a recent drop in the US dollar, the company will be one to follow closely in 2016.

We look forward to seeing you on June 8.

Philippe and Mathieu

Disclosure: Philippe and Mathieu own shares of ProMIS Neurosciences. Mathieu also owns shares of Imaflex and Hamilton Thorne.